Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Hager

Surgery Pittsburgh, PA Medical Doctor

NPI 1083814933 CMS profile 1020656

200 Lothrop St, Pittsburgh, PA 15213

Open in the dashboard

General payments

$41,356

83 records reported · program years 2019–2025

Research payments

$2,369

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Hager of Pittsburgh, PA is reported in the CMS Open Payments database as having received $41,356 across 83 general payments and $2,369 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,789 16
2024 General $11,326 26
2023 General $7,791 19
2022 General $4,353 4
2021 General $143 3
2020 General $1,898 9
2019 General $1,056 6
2019 Research $2,369 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Hager
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Eric Hager were reported at $14,789. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Eric Hager Surgery median Middle half National median
2019 $1,056 $253 $82–$1,521 $163
2020 $1,898 $131 $40–$706 $114
2021 $143 $168 $50–$904 $132
2022 $4,353 $224 $76–$1,218 $149
2023 $7,791 $253 $82–$1,255 $160
2024 $11,326 $279 $90–$1,381 $164
2025 $14,789 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $18,624 25 payments
  2. Bard Peripheral Vascular, Inc. $14,121 25 payments
  3. Cook Incorporated $4,000 1 payment
  4. AngioDynamics, Inc. $1,950 2 payments
  5. W. L. Gore & Associates, Inc. $1,044 6 payments
  6. Silk Road Medical, Inc. $650 5 payments
  7. Tactile Systems Technology Inc $322 6 payments
  8. Cook Medical LLC $229 3 payments
  9. LeMaitre Vascular, Inc. $119 1 payment
  10. Medtronic Vascular, Inc. $91 2 payments
  11. Other $207 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,600 6 payments
  2. Consulting Fee $14,300 8 payments
  3. Food and Beverage $3,802 52 payments
  4. Travel and Lodging $3,463 15 payments
  5. Education $191 2 payments
Products named General payments · program years 2019–2025
  1. ClosureFast $9,539 8 payments
  2. VENASEAL $9,039 14 payments
  3. ZILVER PTX $4,000 1 payment
  4. Venclose Maven Catheter $1,511 15 payments
  5. ENROUTE Transcarotid Neuroprotection System $650 5 payments
  6. ENROUTE Transcarotid Stent System $650 5 payments
  7. ENHANCE Transcarotid Peripheral Access Kit $650 5 payments
  8. ENROUTE 0.014 Guidewire $650 5 payments
  9. GORE VIABAHN Endoprosthesis with Heparin $410 2 payments
  10. GORE VIABAHN VBX Balloon Expandable Endo $189 1 payment
  11. Other $2,001 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AngioDynamics, Inc. $2,369 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

60

Median for Vascular Surgery: 122

Drug cost

$35,011

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 14 $18,226
Xarelto Rivaroxaban Brand 19 $16,607
Clopidogrel Clopidogrel Bisulfate Brand 27 $178

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$74,434

Medicare's payments for the services billed

Medicare patients

463

Average age 73

Services billed

724

241 women, 222 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Ischemic heart disease 49%
Chronic kidney disease 46%
Diabetes 42%
Heart failure 39%
Atrial fibrillation 32%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record